Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Flash Glucose Monitoring Continues to Grow Despite the Presence of CGM Industry
Fish and Poultry Nutritional Benefits for Weight Loss Fish and poultry are excellent additions to your diet when paired with GLP-1 therapy, offering lean protein without piling on extra calories or saturated fat
Both acarbose and voglibose are effective in controlling postprandial blood glucose levels, with no significant difference in control
Medvi primarily offers online medical weight-loss care, with access to prescription treatments, including GLP-1 options for those who qualify
With a list of associated health problems that could rival a horror movie marathon, it's time to find the superhero to save the day
